ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States (“Scheme”), under which Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme.

澳大利亚阿德莱德和马萨诸塞州剑桥，2024年12月16日（环球通讯社）--Bionomics Limited（Nasdaq:BNOX）（Bionomics或Company）很高兴地宣布，澳大利亚新南威尔士州最高法院（“法院”）今天发布命令，批准公司拟从澳大利亚迁至美国的安排计划（“计划”），根据该计划，特拉华州公司Neuphoria Therapeutics Inc.，一家公司（“Neuphoria”），将在该计划实施后成为Bionomics Limited的最终母公司。

A copy of the Court’s orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following the Court hearing, at which time the Scheme became legally effective. Bionomics’ ADSs will continue to trade on Nasdaq until the implementation date (December 23, 2024 (New York time)).

在法庭听证会之后，法院关于该计划的命令副本已提交给澳大利亚证券投资委员会，该计划在当时具有法律效力。Bionomics的ADS将继续在纳斯达克交易，直到实施日期（2024年12月23日（纽约时间））。

Bionomics shareholders who hold shares on the record date for the Scheme (5:00pm Sydney time on Tuesday, December 17, 2024) will be entitled to receive the Scheme consideration (in accordance with the terms of the Scheme as set out in Section 6 of the Scheme Booklet dated November 11, 2024 (“Scheme Booklet”)).

在计划记录日期（2024年12月17日，悉尼时间周二下午5:00）持有股份的Bionomics股东将有权获得计划对价（根据2024年11月11日计划手册（“计划手册”）第6节规定的计划条款）。

The Scheme consideration will be paid to Scheme Shareholders (as defined in the Scheme Booklet) on the implementation date. Shares of Neuphoria are expected to begin trading on Nasdaq under the symbol “NEUP” on December 24, 2024 or as soon as possible thereafter. FOR FURTHER INFORMATION PLEASE CONTACT: GeneralRajeev Chandra Company SecretaryCoSec@bionomics.com.auInvestor RelationsKevin Gardnerkgardner@lifesciadvisors.comInvestor RelationsChris Calabreseccalabrese@lifesciadvisors.com    About Bionomics LimitedBionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, pot.

。Neuphoria的股票预计将于2024年12月24日或之后尽快在纳斯达克开始交易，代号为“NEUP”。欲了解更多信息，请联系：GeneralRajeev Chandra CompanySecretaryCoSec@bionomics.com.auInvestor关系凯文Gardnerkgardner@lifesciadvisors.comInvestor关系学Calabreseccalabrese@lifesciadvisors.com关于Bionomics Limited Bionomics（纳斯达克股票代码：BNOX）是一家临床阶段的生物技术公司，开发新型pot。